Oral vs Injectable Semaglutide Side Effects: Analysis of 19,000+ Adverse Event Reports

GI disorders accounted for 30.19% of oral and 27.76% of subcutaneous semaglutide adverse events. Novel signals included pancreatic failure (ROR 36.34) for injectable and Dupuytren's contracture (ROR 46.85) for oral semaglutide.

Pharmacovigilance analysis of 19,289 semaglutide adverse events from FDA FAERS database (Q1 2018-Q2 2023) and 422 patient reviews from WebMD and AskaPatient. Calculated reporting odds ratios (ROR) to identify disproportionate safety signals. Compared oral vs subcutaneous formulations.

With millions of patients choosing between oral and injectable semaglutide, understanding the different side effect profiles helps inform that choice. Identifying new safety signals in such a widely used drug is critical for patient safety monitoring.

Semaglutide is one of the most prescribed drugs worldwide, but its rapid adoption means long-term safety data is still emerging. Post-marketing surveillance through databases like FAERS provides early warning signals that clinical trials — with their limited duration and selected populations — may miss. These findings don't prove causation but warrant further investigation.

FAERS data is based on voluntary reporting, which introduces significant biases — adverse events are underreported and reporting rates vary by severity and publicity. Social media data is unverified. ROR signals indicate disproportionate reporting, not causation or incidence rates. Novel signals (pancreatic failure, Dupuytren's) need confirmation in controlled studies.